Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong

INTRODUCTION: Lower-dose ceritinib (450 mg) once-daily with food was approved in 2018 in Hong Kong (HK) for first-line treatment of patients with anaplastic lymphoma kinase-positive (ALK +) advanced non-small cell lung cancer (NSCLC). This study examined the cost-effectiveness of ceritinib vs. crizo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cost Eff Resour Alloc
Autores principales: Loong, Herbert H., Wong, Carlos K. H., Leung, Linda K. S., Chan, Catherine P. K., Chang, Andrea, Zhou, Zheng-Yi, Xie, Jipan, Gibbs, Meaghan
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648263/
https://ncbi.nlm.nih.gov/pubmed/33292314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12962-020-00244-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares